



# BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

## ESPS PEER REVIEW REPORT

**Name of journal:** World Journal of Stem Cells

**ESPS manuscript NO:** 12501

**Title:** Could cancer and infection be adverse effects produced by using multipotent mesenchymal stromal cell therapy?

**Reviewer code:** 02446163

**Science editor:** Xiu-Xia Song

**Date sent for review:** 2014-07-12 15:11

**Date reviewed:** 2014-07-31 17:37

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> Existing	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> Existing	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

### COMMENTS TO AUTHORS

Peer review disclosure form Please check the boxes as appropriate Financial disclosure  I have no relevant financial interests or conflicts related to this manuscript OR  I certify that my affiliations with (personal or financial relationships that could influence your actions) or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript have been disclosed. Financial involvement refers to: employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, royalties.